The Canadian subsidiary of engineering and construction firm Fluor Daniel of Irvine, CA, has won a contract to process medical radioisotopes produced by the Maple reactor complex being built by Atomic Energy of Canada (AECL). Fluor Daniel Canada will
The Canadian subsidiary of engineering and construction firm Fluor Daniel of Irvine, CA, has won a contract to process medical radioisotopes produced by the Maple reactor complex being built by Atomic Energy of Canada (AECL). Fluor Daniel Canada will construct a processing facility near the Maple complex to house hot cells, which are used for the separation of isotopes.
AECL is building the Maple reactors to provide a stable supply of radioisotopes such as molybdenum, the raw material for technetium-99m, a commonly used radioisotope in nuclear medicine studies. The age of the existing AECL reactor that is being used to produce molybdenum has concerned nuclear medicine physicians, and a labor dispute at AECL caused a brief shutdown of molybdenum shipments last summer (SCAN 7/9/97). The Maple reactors are scheduled to be completed by 1999, with medical isotope production beginning some time after that.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).